Table 2.

Patient characteristics of the GenomeDX cohorts stratified by lowest tristetraprolin quartile

TristetraprolinLow (n = 197)TristetraprolinHigh (n = 591)P value
Study cohort, n (%)<0.001
 CCF6 (6)101 (94)
 JHU96 (36)170 (64)
 MSK2 (13)14 (88)
 Mayo Ia78 (30)186 (70)
 Mayo II15 (11)120 (89)
Age at diagnosis, median (SD; range)63.0 (6.8, 38–77)62.5 (6.9, 42–79)0.22
Pathologic RP Gleason score, n (%)0.043
 2–612 (14)72 (86)
 768 (24)217 (76)
 833 (25)99 (75)
 9–1084 (29)203 (71)
Clinical stage, n (%)0.31
 T1/T2173 (24)534 (76)
 T324 (30)57 (70)
Adjuvant ADT, n (%)b0.91
 No62 (23)202 (77)
 Yes31 (23)104 (77)
Adjuvant RT, n (%)b0.63
 No80 (23)269 (77)
 Yes13 (26)37 (74)
Total PSA at diagnosis, ng/mL, n (%)0.036
 0–420 (26)57 (74)
 4–1084 (24)271 (76)
 10–2047 (23)155 (77)
 >2044 (34)85 (66)
 Not available2 (8)23 (92)
Case status, n (%)<0.001
 Lethal120 (30)278 (70)
 Indolent77 (20)313 (80)
  • Abbreviation: RP, radical prostatectomy.

  • aMayo I and II refer to distinct patient cohorts that were used in the original discovery and validation, respectively, of GenomeDx Decipher genomic classifier (Erho, 2013).

  • bBased on total n = 399 (93 TristetrapolinLow, 309 TristetrapolinHigh).